Search clinical trials for: Risankizumab, Skyrizi, Crohn's Disease, ABBV-066

Total 2214 results

AbbVie

Recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Hematologic Cancer

United States, Israel, Japan
TeneoOne Inc.

Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Israel, United States, Canada, Spain, France, Denmark, United Kingdom
AbbVie

Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | B Cell Malignancies

United States, Israel, Australia, France, United Kingdom, Belgium, Spain
AbbVie

Recruiting

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, France, Poland
AbbVie

Recruiting

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Chronic Lymphocytic Leukemia

United States, Australia, Canada, Israel
AbbVie

Available

Expanded Access to ABBV-787

Acute Myeloid Leukemia
AbbVie

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Parkinson's Disease (PD)

United States
AbbVie

Completed

A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

Advanced Solid Tumors Cancer

Japan
AbbVie

Terminated

A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

Advanced Solid Tumors Cancer

United States, Australia, Denmark, Spain
AbbVie

Available

Expanded Access to Telisotuzumab Vedotin

Non-Small Cell Lung Cancer (NSCLC)

Australia, Hong Kong, Israel, United States, Germany
AbbVie

Terminated

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

Psoriasis

United States, Canada, Japan
AbbVie
Genmab

No longer available

Expanded Access to Epcoritamab

Lymphoma
Calico Life Sciences LLC
AbbVie

Recruiting

An Open-Label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease

Vanishing White Matter Disease

United States, Netherlands
AbbVie

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Germany
AbbVie

Terminated

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

Colorectal Cancer

United States
AbbVie

Completed

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Pancreatic Cancer

United States, Australia, Israel, Korea, Republic of, Puerto Rico, Spain
Genmab
AbbVie

Recruiting

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Non-hodgkin Lymphoma

United States, Australia, France, Israel, Korea, Republic of, Spain, Taiwan, Japan, Italy, Belgium, Germany, Canada, Turkey, Czechia
Calico Life Sciences LLC
AbbVie

Active, not recruiting

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis | ALS

United States, Canada
AbbVie

Active, not recruiting

A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Australia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Taiwan
AbbVie

Completed

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

Rheumatoid Arthritis (RA)

United States, Belgium, Canada, Czechia, Hungary, Poland, Puerto Rico, Spain, United Kingdom
AbbVie

Recruiting

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-1)

Hepatocellular Carcinoma

United States, Japan, Taiwan, Korea, Republic of, Spain, France, Italy
AbbVie

Completed

ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck | Undifferentiated Pleomorphic Sarcoma | Carcinoma of the Breast

United States, France, Spain
AbbVie

Recruiting

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2)

Hepatocellular Carcinoma

United States, Taiwan, Spain, France
AbbVie

Withdrawn

An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)

Sjogren's Syndrome (SS)

Netherlands
Biocad

Completed

Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers

Healthy

Russian Federation
AbbVie

Recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Israel, Japan, Australia, Spain, Germany
AbbVie

Completed

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Ulcerative Colitis (UC)

United States, Canada, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom
AbbVie

Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab

Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States, Japan, Israel, Korea, Republic of
AbbVie

Completed

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) (SLEek)

Systemic Lupus Erythematosus (SLE)

United States, Argentina, Australia, Bulgaria, Canada, China, Colombia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Spain, Taiwan, United Kingdom
Biocad

Completed

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Healthy

Russian Federation
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

Alzheimer's Disease

United States, Australia, Belgium, Canada, Denmark, Finland, Italy, Netherlands, New Zealand, Spain, Sweden
AbbVie

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Hepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell Carcinoma

United States, Israel, Japan, Puerto Rico, Korea, Republic of, Taiwan
AbbVie

Terminated

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

Glioblastoma Multiforme | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Colorectal Carcinoma

United States, Spain
AbbVie

Completed

A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration

Healthy Volunteer

United States
AbbVie

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA)

United States, Germany, Hungary, Israel, Netherlands, Poland, Puerto Rico
AbbVie

Completed

A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

Systemic Lupus Erythematosus (SLE)

United States, Argentina, Australia, Bulgaria, China, Colombia, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Puerto Rico, Spain, Taiwan, United Kingdom
AbbVie

Completed

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Advanced Solid Tumors Cancer

United States, Australia, Israel
AbbVie

No longer available

Expanded Access to ABBV-8E12

Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)
Merck Sharp & Dohme LLC

Completed

MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

Type 2 Diabetes Mellitus
Memorial Sloan Kettering Cancer Center

Completed

Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma

Mesothelioma

United States
AbbVie

Not yet recruiting

Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers

Healthy Volunteers
AbbVie

Terminated

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

Rheumatoid Arthritis (RA)

Belgium, Canada, Czechia, Hungary, Poland, Spain, United Kingdom
AbbVie

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion

Immunoglobulin Light Chain (AL) Amyloidosis

Japan, United States, Australia
AbbVie

Completed

A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants

Dry Eye Syndrome

United States
AbbVie

Active, not recruiting

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Cancer | Advanced Solid Tumors | Metastatic Solid Tumors | Triple-Negative Breast Cancer (TNBC) | Non-small-cell-lung-cancer (NSCLC)

United States, Australia, France, Israel, Spain, Taiwan
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

Intrahepatic Cholangiocarcinoma | Cholangiocellular Carcinoma | Peripheral Cholangiocarcinoma | Cholangiolar Carcinoma

United States
Integrative Health Technologies, Inc.
MannaRelief Ministries

Unknown

Study of Parental Ratings of Quality of Life and Body Composition in 5-19 Year Olds While Participating in the Good NEWS 4 Kids Program

Quality of Life | Body Mass Index

United States
Merit E. Cudkowicz, MD
Massachusetts General Hospital

Active, not recruiting

HEALEY ALS Platform Trial - Master Protocol

Amyotrophic Lateral Sclerosis

United States
AbbVie

Completed

A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration

Healthy Volunteer

United States
Southwest Oncology Group

Completed

Lung-MAP S1400K: c-MET Positive

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC V7

United States

3

Subscribe